Development, synthesis, and biological evaluation of (-)-trans-(2S, 5S)-2-[3-[(2-oxopropyl) sulfonyl]-4-n-propoxy-5-(3-hydroxypropoxy)-phenyl]-5-(3, 4, 5- …

…, MM Ponpipom, JJ Acton, AW Alberts…

Index: Girotra, N. N.; Biftu, T.; Ponpipom, M. M.; Acton, J. J.; Alberts, A. W.; et al. Journal of Medicinal Chemistry, 1992 , vol. 35, # 19 p. 3474 - 3482

Full Text: HTML

Citation Number: 33

Abstract

Merck Research Laboratories, PO Box 2000, Rahway, New Jersey 07065. Received February 27, 1992 (-)-trans-(2S, sS)-2-[3-[(2-0xopropyl) sulfonyl]-4-n-propoxy-5-(3- hydroxypropoxy) phenyl]-5-(3, 4, 5-trimethoxy-pheny1) tetrahydrofuran (10) is one of the most potent platelet-activating factor (PAF) antagonists in vitro and in vivo developed to date. This diaryltetrahydrofuran derivative evolved from modifications of MK 0287 which has ...